Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Terminated 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Liver Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 212Irinotecan 145Leucovorin 139Gemcitabine 125S 1 (combination) 110apatinib 109Cisplatin 102Drug Therapy 98Radiotherapy 97Paclitaxel 97Bevacizumab 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54toripalimab 53Sorafenib 53Folfox protocol 53Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Axitinib × Gastrointestinal × Clear all
NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡